Compare Matson Inc (MATX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Mesoblast Limited — how do they compare? Matson Inc trades at $222.13 (market cap $6.61B), while Mesoblast Limited trades at $16.36 (market cap $2.17B). The key difference: Matson Inc is far larger — about 3× Mesoblast Limited's market cap, and Matson Inc pays a 0.7% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MATX | MESO | |
|---|---|---|
Market Cap | $6.61B | $2.17B |
Sector | Technology | Technology |
52-Week High | $223.55 | $20.96 |
52-Week Low | $88.05 | $12.88 |
Enterprise Value | $7.21B | $2.17B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $218.41, down 1.7% today but maintains a bullish technical outlook with strong moving averages and key support at $214. The company demonstrates solid fundamentals with a P/E of 16.48, net income margin of 12.92%, and consistent earnings beats in recent quarters. Recent news highlights preliminary Q2 2026 results expecting EPS of $4.12-$4.30 and a dividend increase to $0.38 per share, reflecting management confidence.
The investment outlook remains positive given analyst consensus of 63.64% buy ratings, robust cash flow from operations, and strategic fleet modernization. Key risks include exposure to Pacific trade volatility and potential economic slowdowns impacting shipping demand. The stock's current valuation and growth trajectory present a compelling opportunity for investors seeking stable dividends and earnings growth in the shipping sector.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
